Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1030 | 1171 | 1145 | 1092 | 1511 | 2102 |
Fund Return | 2.99% | 17.09% | 14.54% | 2.98% | 8.61% | 7.71% |
Place in category | 123 | 118 | 81 | 17 | 18 | 10 |
% in Category | 45 | 48 | 30 | 8 | 11 | 13 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Cleome Index USA Equities I USD Acu | 2.23B | 10.19 | 12.03 | - | ||
Cleome Index USA Equities Z USD Acc | 2.23B | 6.76 | 10.40 | 12.02 | ||
RBC Lux GlblEqFocus Class C USD Cap | 1.74B | 1.00 | 6.13 | - | ||
RBC Lux GlblEqFocus Class B USD Cap | 1.74B | 0.96 | 6.02 | - | ||
RBC Lux GlblEqFocus Class A USD Cap | 1.74B | 0.54 | 4.97 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Franklin Biotech Discovery Nacc | 104.28M | 4.88 | -4.60 | 3.64 | ||
Pictet Biotech R USD | 1.46B | -18.92 | 4.74 | 6.44 | ||
Pictet Biotech PUSD | 1.46B | -18.50 | 5.47 | 7.18 | ||
Equities L Biotechnology Class I US | 1.44B | 2.72 | 2.18 | 7.26 | ||
Pictet Biotech P dy USD | 1.46B | 0.77 | -3.47 | 5.68 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Vertex | US92532F1003 | 6.89 | 397.48 | -0.06% | |
Regeneron Pharma | US75886F1075 | 6.42 | 883.20 | -0.84% | |
Amgen | US0311621009 | 5.95 | 269.98 | +0.22% | |
Gilead | US3755581036 | 5.74 | 65.42 | +0.23% | |
AstraZeneca | GB0009895292 | 3.64 | 11,988.0 | -0.32% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Sell | Buy |
Technical Indicators | Strong Sell | Strong Sell | Strong Buy |
Summary | Strong Sell | Strong Sell | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review